Doubled drug substance capacity at Alvotech's Reykjavik, Iceland, site aims to secure steady US supply of the Humira biosimilar Simlandi.
News|Articles|September 22, 2026
Characterizing LNPs: Meeting Regulatory Expectations With FFF-MALS
Author(s)Waters Corporation
This executive summary examines how field-flow fractionation coupled with multi-angle light scattering (FFF-MALS) characterizes lipid nanoparticles (LNPs) as regulatory expectations from FDA, EMA, and USP converge on a shared set of critical quality attributes. It walks through how FFF-MALS resolves particle size, molar mass, and payload distribution in a single non-destructive run, and includes a case study comparing two authorized mRNA vaccines. Readers will see how size-resolved analysis uncovered differences in payload distribution that bulk-average methods missed.
Related to this article
The glucagon/GLP-1 dual agonist hit both weight loss endpoints in phase 3, though gastrointestinal discontinuations and competitor data temper the readout.
CaseBioscience joins an ARPA-H effort to develop room-temperature cell therapy preservation, Novartis licenses an mRNA-encoded T-cell engager from Abogen, and AstraZeneca, Daiichi Sankyo, and Summit plan to combine Datroway with ivonescimab.
LumaLex Law's Dustin Robinson explains why retatrutide compounding remains illegal regardless of the Seventh Circuit's pending classification ruling.
Artiva Biotherapeutics will present data on AlloNK, an allogeneic, non-genetically modified NK cell therapy given with rituximab, in refractory rheumatoid arthritis, Sjögren disease and systemic sclerosis at ACR Convergence 2026, ahead of a planned phase 3 trial in rheumatoid arthritis.
Novartis has secured an exclusive worldwide license to ABO2203, Abogen's investigational mRNA-encoded CD19xCD3 T-cell engager designed to produce the bispecific inside the body to reset B cells in autoimmune disease. The agreement also includes options on other programs built on Abogen's RNA platform.
The 15-month project could let living cell therapies ship and store at room temperature, cutting cold-chain costs that limit patient access.
A planned phase 3 trial will test the TROP2 ADC and PD-1/VEGF bispecific together in 1st-line triple-negative breast cancer.